Skip to main content

Table 2 Sexual and reproductive history of women screened for cervical cancer and proportion of VIA positivity, Addis Ababa, Ethiopia

From: Factors affecting cervical cancer screening uptake, visual inspection with acetic acid positivity and its predictors among women attending cervical cancer screening service in Addis Ababa, Ethiopia

Variable, n = 844

n(%)

Name of health center

  

AH

W1H

SH

FMH

LH

Menstrual History, p = 0.011

 Regularly

382 (45.3)

74 (49.3)

77 (45.3)

92 (47.2)

57 (43.8)

82 (41.2)

 Irregular

290 (34.4)

49 (32.7)

64 (37.6)

63 (32.3)

55 (42.3)

59 (29.6)

 Post coital spotting

7 (0.8)

0 (0)

4 (2.4)

1 (0.5)

1 (0.8)

1 (0.5)

 Menopause

165 (19.5)

27 (18.0)

25 (14.7)

39 (20.0)

17 (13.1)

57 (28.6)

Pregnancy status, p = 0.896

 Pregnant

1 (0.1)

0 (0)

0 (0)

1 (0.5)

0 (0)

0 (0)

 Non-pregnant

843 (99.9)

150 (100)

170 (100)

194 (99.5)

130 (100)

199 (100)

Parity, p = 0.004

 No

119 (14.1)

31 (20.7)

28 (16.5)

25 (12.8)

6 (4.6)

29 (14.6)

 1–3

575 (68.1)

89 (59.3)

99 (58.2)

136 (69.7)

115 (88.5)

136 (68.3)

 4–5

107 (12.7)

24 (16.0)

32 (18.8)

21 (10.8)

4 (3.1)

26 (13.1)

  > 5

43 (5.1)

6 (4.0)

11 (6.5)

13 (6.7)

5 (3.8)

8 (4.0)

Ever use of contraceptive methods, p = 0.009

 No

561 (66.5)

107 (71.3)

117 (68.8)

129 (66.2)

69 (53.1)

139 (69.8)

 Yes

283 (33.5)

43 (28.7)

53 (31.2)

66 (33.8)

61 (46.9)

60 (30.2)

Type of contraceptive method, p = 0.317

 Injectable

86 (30.4)

12 (27.9)

14 (26.9)

22 (33.3)

20 (33.3)

18 (30.0)

 OCP

42 (14.8)

10 (23.4)

8 (15.4)

11 (16.7)

5 (8.4)

6 (10.0)

 IUCD

45 (15.9)

8 (18.6)

10 (19.2)

11 (16.7)

3 (5.0)

13 (21.7)

 Implant

102 (36.0)

11 (25.6)

19 (36.5)

19 (28.8)

30 (50.0)

23 (38.3)

 Tubaligation

1 (0.4)

0 (0)

0 (0)

1 (1.5)

0 (0)

0 (0)

 Condom

7 (2.5)

2 (4.5)

1 (1.9)

2 (3.0)

2 (3.3)

0 (0)

Other corticosteroid use history, p = 0.556

 Yes

2 (0.2)

1 (0.7)

0 (0)

0 (0)

1 (0.8)

0 (0)

 No

842 (99.8)

149 (99.3)

170 (100)

195 (100)

129 (99.2)

199 (100)

Family hx of cervical cancer, p = 0.687

 Yes

5 (0.6)

2 (1.3)

1 (0.6)

1 (0.5)

0 (0)

1 (0.5)

 No

839 (99.4)

148 (98.7)

169 (99.4)

194 (99.5)

130 (100)

198 (99.5)

HIV status, p < 0.0001

 HIV positive

252 (29.9)

64 (42.7)

56 (32.9)

35 (26.9)

53 (27.2)

46 (23.1)

 HIV negative

447 (53.0)

47 (31.3)

81 (47.6)

48 (36.9)

124 (63.6)

146 (73.4)

 Unknown

145 (17.1)

39 (26)

33 (19.4)

47 (36.2)

18 (9.2)

7 (3.5)

STI history

 Yes

247 (29.3)

16 (10.7)

44 (25.9)

55 (28.2)

65 (50.0)

67 (33.7)

 No

597 (70.7)

134 (89.3)

126 (74.1)

140 (71.8)

65 (50.0)

132 (66.3)

VIA test result, p < 0.0001

 Positive

87 (10.3)

8 (5.3))

8 (4.7)

30 (25.4)

11 (8.5))

30 (25.1)

 Negative

757 (89.7)

142 (94.7

162 (95.3)

165 (84.6)

119 (91.5

169 (84.9)

  1. p-value is as per chi-square test done between sexual and reproductive characteristics; and health center type, AH Arada health center, W1H Woreda 1 health center, SH Selam health center, FH Felegemelese health center, LH Lideta health center, OCP Oral contraceptives, IUCD Intrauterine contraceptive device.